Dimerix Ltd (DXB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dimerix Ltd (DXB) has a cash flow conversion efficiency ratio of 3.087x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$41.30 Million) by net assets (AU$13.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dimerix Ltd - Cash Flow Conversion Efficiency Trend (1992–2025)
This chart illustrates how Dimerix Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dimerix Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dimerix Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Francaise de l'Energie
LSE:0RIL
|
0.089x |
|
AVITA MEDICAL DL-0001
F:51KA
|
N/A |
|
Indeks Bilgisayar Sistemleri Muhendislik Sanayi ve Ticaret AS
IS:INDES
|
0.147x |
|
U.S. GoldMining Inc. Common stock
NASDAQ:USGO
|
-0.754x |
|
Omiris AG
F:HBD1
|
N/A |
|
INFUSYSTEMS HLDG.DL-0001
F:1TZ
|
0.124x |
|
VIA Labs Inc
TW:6756
|
-0.028x |
|
Tectonic Metals Inc
V:TECT
|
-0.483x |
Annual Cash Flow Conversion Efficiency for Dimerix Ltd (1992–2025)
The table below shows the annual cash flow conversion efficiency of Dimerix Ltd from 1992 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$13.38 Million | AU$39.05 Million | 2.919x | +857.87% |
| 2024-06-30 | AU$18.19 Million | AU$-7.00 Million | -0.385x | +81.96% |
| 2023-06-30 | AU$5.96 Million | AU$-12.73 Million | -2.135x | -129.17% |
| 2022-06-30 | AU$14.42 Million | AU$-13.44 Million | -0.932x | +78.83% |
| 2021-06-30 | AU$1.47 Million | AU$-6.46 Million | -4.401x | -623.25% |
| 2020-06-30 | AU$7.76 Million | AU$-4.72 Million | -0.608x | +7.03% |
| 2019-06-30 | AU$4.20 Million | AU$-2.75 Million | -0.655x | -39.16% |
| 2018-06-30 | AU$6.86 Million | AU$-3.23 Million | -0.470x | +33.66% |
| 2017-06-30 | AU$2.63 Million | AU$-1.86 Million | -0.709x | -15.29% |
| 2016-06-30 | AU$2.24 Million | AU$-1.38 Million | -0.615x | -205.76% |
| 2015-06-30 | AU$2.78 Million | AU$-558.55K | -0.201x | +58.31% |
| 2014-06-30 | AU$1.18 Million | AU$-568.88K | -0.482x | +97.30% |
| 2014-04-30 | AU$31.22K | AU$-558.55K | -17.893x | -9885.60% |
| 2013-06-30 | AU$1.71 Million | AU$-305.90K | -0.179x | +9.01% |
| 2012-06-30 | AU$1.18 Million | AU$-232.33K | -0.197x | +5.57% |
| 2011-06-30 | AU$1.57 Million | AU$-326.54K | -0.209x | +12.93% |
| 2010-06-30 | AU$1.56 Million | AU$-373.67K | -0.240x | +95.32% |
| 2009-06-30 | AU$341.98K | AU$-1.75 Million | -5.113x | -114.66% |
| 2008-06-30 | AU$1.01 Million | AU$-2.40 Million | -2.382x | -103.42% |
| 2007-06-30 | AU$1.41 Million | AU$-1.66 Million | -1.171x | -56.68% |
| 2006-06-30 | AU$2.69 Million | AU$-2.01 Million | -0.747x | -405.76% |
| 2005-06-30 | AU$10.28 Million | AU$-1.52 Million | -0.148x | -102.79% |
| 2004-06-30 | AU$-170.38K | AU$-902.37K | 5.296x | +422.93% |
| 2003-06-30 | AU$-565.02K | AU$-572.26K | 1.013x | +147.45% |
| 2002-06-30 | AU$282.89K | AU$-603.82K | -2.135x | -1434.07% |
| 2001-06-30 | AU$640.43K | AU$102.47K | 0.160x | +74.25% |
| 2000-06-30 | AU$5.24 Million | AU$481.16K | 0.092x | -48.60% |
| 1999-06-30 | AU$5.77 Million | AU$1.03 Million | 0.179x | +303.76% |
| 1997-06-30 | AU$1.96 Million | AU$-171.60K | -0.088x | -29.69% |
| 1996-06-30 | AU$1.85 Million | AU$-125.03K | -0.068x | +5.26% |
| 1995-06-30 | AU$1.72 Million | AU$-123.00K | -0.071x | -16.09% |
| 1994-06-30 | AU$1.74 Million | AU$-107.00K | -0.061x | -147.59% |
| 1993-06-30 | AU$1.41 Million | AU$-35.00K | -0.025x | -299.35% |
| 1992-06-30 | AU$1.04 Million | AU$13.00K | 0.012x | -- |
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more